Good Clinical Practice
Developed in alignment with GCP principles and clinical research standards.
Platform & Research · The infrastructure behind Boli Care
One platform powering obesity care and real‑world research.
Boli Care is a digital therapeutic for people living with obesity - and their physicians.
Daily care for patients, decision-support for physicians, structured real-world data for clinical researchers, built as one coherent system for obesity, metabolic and cardiometabolic disease.
Clinical research
See the research roadmap
A research-ready platform from day one.
By embedding structured data collection directly into routine care, Boli Care generates longitudinal clinical and patient-reported data in real-world conditions - ready for observational studies, real-world cohorts, and collaborative clinical research across borders, including treatment journeys on anti-obesity medications (such as GLP-1/GIP).
Built for future studies
Designed to support observational studies, real-world cohorts, and research collaborations.
Build with us
Run your next obesity study on real-world infrastructure.
Whether you're a clinical investigator, a pharma RWE team, an HTA agency, or a patient organization, we'd love to hear about your project. We share detailed protocols and roadmaps under NDA.
What we build
A complete clinical platform.
Four complementary products on a unified stack to capture the clinical, behavioural and scientific dimensions of obesity care under anti-obesity medication therapy.
The patient companion app
A medical companion for people on anti-obesity medications. Daily check-ins on tolerance, side effects, mood, sleep, eating behaviour and adherence; therapeutic education content validated by physicians; longitudinal tracking that builds, day after day, the patient's own clinical narrative.
- Daily structured PRO collection
- GLP-1 side-effect guidance
- Adapted nutrition & behavioural support
The clinician console
A clinical-grade interface for physicians: a synthesized view of each patient on AOMs, longitudinal trends, contextual and graduated alerts, and structured patient-reported outcomes ready for the consultation. Built around the realities of obesity care pathways, not generic telehealth.
- Remote patient monitoring
- Synthesized patient view & contextual alerts
- PRO-grade evidence ready for the consultation
The digital phenotyping engine
A 12-dimension engine of health determinants, for a unique view of each patient.
- AI on biological, behavioural & contextual signals
- Clinical-grade phenotype
- Weekly model updates
The research data infrastructure
A research-grade data layer designed for real-world evidence on obesity care and GLP-1 therapy. Ready for clinical studies, pharma collaboration and regulatory submission, with a full audit trail and GCP alignment from day one.
- Real-world evidence (RWE), GCP-aligned
- Full audit trail by design
- Ready for clinical & pharma collaboration
Boli's clinical evidence program, publications to HTA-grade evidence.
You don't reshape a medical field by ignoring its codes. Boli Care is running its own multi-year clinical research program, internally designed, funded and executed, from first scientific commentaries to the pivotal trials and health-economic studies that HTA bodies and payers require.
- 11Boli-led studies in the pipeline
- FR · EN · ESmulti-country internal cohorts
- 18 publicationsplanned over 4 years
- HTA-gradehealth-economic dossier
Boli-led · Internal research portfolio
11 Boli-led studies, from first commentary to pivotal RCT and HTA dossier.
High-level view of our internal studies, all Boli-designed, Boli-funded, Boli-executed. Detailed protocols, endpoints and timelines are shared under NDA.
| ID | Type | Phase | Status | Details |
|---|---|---|---|---|
| BOLI-001 | Scientific commentary | Phase 1 | Ready to submit | On request |
| BOLI-002 | International cross-sectional survey | Phase 1 | In design | On request |
| BOLI-003 | Prospective digital cohort | Phase 2 | In preparation | On request |
| BOLI-004 | Systematic review & meta-analysis | Phase 1 | In preparation | On request |
| BOLI-005 | Single-arm feasibility study | Phase 2 | Planned | On request |
| BOLI-006 | Side-effect management performance | Phase 2 | Planned | On request |
| BOLI-007 | Monocentric randomized controlled trial | Phase 3 | Planned | On request |
| BOLI-008 | Mechanistic / mediation analysis | Phase 3 | Planned | On request |
| BOLI-009 | Multicenter prospective evaluation | Phase 4 | Planned | On request |
| BOLI-010 | Health economic evaluation | Phase 4 | Planned | On request |
| BOLI-011 | Definitive multicenter RCT | Phase 5 | Planned | On request |
This is Boli's internal research agenda, endpoints, sample sizes, sites and timelines are confidential. Contact research@boli.care for the detailed brief, co-authorship opportunities or HTA-oriented collaborations.
Why Boli for research
A research infrastructure unlike site-based registries.
Patient-first capture
Direct patient-reported outcomes, weekly cadence, multi-country, not a site coordinator's translation of what they remember.
Between-visit signal
Capturing data where chronic disease actually plays out, across the weeks between consultations, not the snapshot of a single visit. That is precisely where classical clinical trials stop.
Multilingual cohorts
FR · EN · ES from day one, with active patient communities reaching across Europe, the Americas, and Spanish-speaking world.
Standards-aligned
ICHOM Adult Obesity Standard Set, GCP-aligned data model, OMOP-friendly schema, CTCAE-aligned PRO grading.
Real-world signals, behind the platform.
Long-form articles grounded in published evidence and our own real-world cohorts.
Wegovy vs Mounjaro: real-world data in 2026
Beyond STEP-1 and SURMOUNT-1: SURMOUNT-5 head-to-head, real-world persistence and tolerability, and how the choice is being made today.
Why half of GLP-1 patients stop in the first year
Real-world persistence data, the four most consistent reasons for discontinuation, and what evidence-based daily support changes.
Stopping GLP-1: what the evidence says
The STEP-1 extension and SURMOUNT-4 trial, what they say about discontinuing semaglutide and tirzepatide, and how to plan for it.
Receive the Boli Care brochure.
A printable document covering the medical device, the patient app, the physician dashboard and the science behind digital phenotyping. Sent to your inbox in seconds, in English.
- Class I medical device, CE marked, EU MDR 2017/745
- Real-world AOM follow-up between two consultations
- Built with French endocrinologists and obesity specialists
Get the brochure by email
Free · no follow-up unless you askBrochure on its way.
We've just sent the Boli Care brochure to your inbox. If you don't see it within a couple of minutes, please check your spam folder.
Something went wrong.
We could not send the brochure right now. Please try again, or write to us at hello@boli.care.